No Data
Regulatory Delays Pressure Humacyte's (HUMA) Cash Reserves
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
Humacyte (HUMA) Insiders Show Confidence Despite Stock Decline
Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024
Humacyte to Present Efficacy and Safety Results From V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
BFSkinner : No, it was doing well til they got their wrist slapped for cutting corners in their research
104983812 OP : so will it crawl bk feel like selling to cut losses hold for 5 months already
Flowerhill : I should have got out long time ago or when the politicians sold them. I like their products though.